EVO756

DRUG2 trials

Sponsors

Evommune, Inc.

Conditions

Atoptic DermatitisChronic Spontaneous Urticaria

Phase 2

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

CompletedNCT06873516

Evommune, Inc.Chronic Spontaneous Urticaria

Start: 2025-03-20End: 2026-06-05Updated: 2026-07-01

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Active, not recruitingNCT07150845

Evommune, Inc.Atoptic Dermatitis

Start: 2025-08-26End: 2026-07-01Target: 120Updated: 2026-05-18